Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03925532 · ClinicalTrials.gov registry record · Phase 2
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03925532 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT03925532, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This Phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, leading to a decrease in satisfaction and quality of life. A type of immunotherapy drug called denosumab binds to a protein called RANKL, which may help keep bone from breaking down.
Interventions
- BIOLOGICAL Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03925532
The ClinicalTrials.gov registry entry for NCT03925532 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Denosumab is the first listed.
NCT03925532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03925532 about?
NCT03925532 is a clinical study titled "Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant". This Phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, lead...
What is the current status of trial NCT03925532?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-12-19. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT03925532?
The interventions under investigation include: Denosumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03925532?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.